The EVADIAC experience

Abstract The EVADIAC association (EVAluation dans le Diabete des Implants ACtifs) was created in 1990 in Cassis, France, at the beginning of implanted insulin pump treatment in France. In fact the first four centers (Strasbourg, Marseille, Montpellier, Toulouse) experiencing the treatment by continous intraperitoneal insulin infusion with implantable pumps (CIPII) derided to join in a group with the primary objective to monitor the safety of the technique. The founding members built the statutes of EVADIAC and the goals were defined as: • Collecting and spreading all the required elements in order to assess the quality of the diabetes treatment by active implants. • Evaluating the benefits of such a treatment in patients with diabetes in order to improve its use. • Promoting every study and research about this kind of treatment. • Communicating with all the related national and international organizations. Due to the impulse of the first president, Ph. Vague, and his successors (M. Pinget, J.P. Tauber, J.L. Selam, V. Lassmann-Vague, E. Renard, H. Hanaire-Broutin), the group enlarged and gathers now 14 centers: Bordeaux, Corbeil, Dijon, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris, Reims, Rennes. St Etienne, Strasbourg, Toulouse. The energy and enthusiasm of all EVADSAC members have allowed a large development and a broad experience of insulin implanted pumps treatment in France.

[1]  V. Lassmann-Vague,et al.  Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. , 2003, Diabetes & metabolism.

[2]  N. Jeandidier,et al.  Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. , 2002, Diabetes care.

[3]  R. Bergman,et al.  Determination of Portal Insulin Absorption From Peritoneum via Novel Nonisotopic Method , 1990, Diabetes.

[4]  C Jaffiol,et al.  Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility , 1996, Diabetes Care.

[5]  N. Jeandidier,et al.  French multicentre experience of implantable insulin pumps , 1994, The Lancet.

[6]  H. Gin,et al.  Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study. , 2006, Diabetes & metabolism.

[7]  E. Renard,et al.  Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. , 2002, Diabetes & metabolism.

[8]  D. Raccah,et al.  Immunogenicity of Long-Term Intraperitoneal Insulin Administration With Implantable Programmable Pumps: Metabolic consequences , 1995, Diabetes Care.

[9]  N. Jeandidier,et al.  Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices , 1995, Diabetologia.

[10]  D. Raccah,et al.  Insulin Kinetics in Type I Diabetic Patients Treated by Continuous Intraperitoneal Insulin Infusion: Influence of Anti‐insulin Antibodies , 1996, Diabetic Medicine.

[11]  V. Karsten,et al.  Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. , 2001, Diabetes care.

[12]  Complications of the Pump Pocket May Represent a Significant Cause of Incidents With Implanted Systems for Intraperitoneal Insulin Delivery , 1994, Diabetes Care.

[13]  E. Renard,et al.  Improved stability of insulin delivery from implanted pumps using a new preparation process for infused insulin. , 1999, Diabetes care.

[14]  E. Renard,et al.  Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study , 1995, Diabetes Care.

[15]  E. Renard,et al.  Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. , 2001, Diabetes & metabolism.

[16]  V. Lassmann-Vague,et al.  Local Adverse Events Associated With Long-Term Treatment by Implantable Insulin Pumps: The French EVADIAC Study Group experience , 1998, Diabetes Care.

[17]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[18]  N. Wong,et al.  Insulin Antibody Responses After Long-Term Intraperitoneal Insulin Administration via Impiantatile Programmable Insulin Delivery Systems , 1994, Diabetes Care.

[19]  G. Charpentier,et al.  Extreme subcutaneous insulin resistance successfully treated by an implantable pump. , 2001, Diabetes care.

[20]  H Gin,et al.  Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. , 2003, Diabetes & metabolism.